| Primary |
| Product Used For Unknown Indication |
23.2% |
| Maternal Exposure Timing Unspecified |
12.3% |
| Ill-defined Disorder |
10.2% |
| In Vitro Fertilisation |
8.5% |
| Prophylaxis |
6.8% |
| Hormone Replacement Therapy |
6.5% |
| Infertility |
4.4% |
| Drug Exposure During Pregnancy |
3.4% |
| Maternal Exposure During Pregnancy |
3.1% |
| Ovarian Hyperstimulation Syndrome |
3.1% |
| Luteal Phase Deficiency |
2.7% |
| Drug Use For Unknown Indication |
2.4% |
| Ovulation Induction |
2.4% |
| Hypothyroidism |
2.0% |
| Menorrhagia |
2.0% |
| Anaesthesia |
1.4% |
| Menopausal Symptoms |
1.4% |
| Menopause |
1.4% |
| Oestrogen Replacement Therapy |
1.4% |
| Pregnancy |
1.4% |
|
| Intra-uterine Death |
14.3% |
| Ectopic Pregnancy |
8.6% |
| Maternal Drugs Affecting Foetus |
8.6% |
| Premature Separation Of Placenta |
8.6% |
| Foetal Exposure During Pregnancy |
7.1% |
| Nausea |
5.7% |
| Death Neonatal |
4.3% |
| Headache |
4.3% |
| Maternal Exposure During Pregnancy |
4.3% |
| Pruritus |
4.3% |
| Uterine Haemorrhage |
4.3% |
| Abdominal Discomfort |
2.9% |
| Abortion Spontaneous |
2.9% |
| Drug Exposure During Pregnancy |
2.9% |
| Drug Ineffective |
2.9% |
| Encephalopathy |
2.9% |
| Exposure During Pregnancy |
2.9% |
| Medication Error |
2.9% |
| Paresis |
2.9% |
| Product Substitution Issue |
2.9% |
|
| Secondary |
| Hormone Replacement Therapy |
49.1% |
| Product Used For Unknown Indication |
8.1% |
| Menopausal Symptoms |
7.4% |
| In Vitro Fertilisation |
5.3% |
| Hot Flush |
3.5% |
| Drug Use For Unknown Indication |
3.2% |
| Menopause |
3.1% |
| Infertility |
2.3% |
| Assisted Fertilisation |
1.9% |
| Hypertension |
1.7% |
| Maternal Exposure Timing Unspecified |
1.7% |
| Ovulation Induction |
1.6% |
| Anxiety |
1.6% |
| Night Sweats |
1.6% |
| Oestrogen Replacement Therapy |
1.6% |
| Ill-defined Disorder |
1.5% |
| Mood Swings |
1.3% |
| Hypothyroidism |
1.2% |
| Depression |
1.2% |
| Weight Decreased |
1.0% |
|
| Breast Cancer |
39.2% |
| Breast Cancer Female |
16.3% |
| Breast Cancer Metastatic |
12.0% |
| Vaginal Haemorrhage |
3.2% |
| Maternal Exposure During Pregnancy |
2.9% |
| Pyrexia |
2.7% |
| Contralateral Breast Cancer |
2.4% |
| Ovarian Cancer |
2.1% |
| Premature Baby |
2.1% |
| Myocardial Infarction |
1.9% |
| Premature Separation Of Placenta |
1.9% |
| Weight Decreased |
1.9% |
| Headache |
1.6% |
| Loss Of Consciousness |
1.6% |
| Ovarian Hyperstimulation Syndrome |
1.6% |
| Arthralgia |
1.3% |
| Completed Suicide |
1.3% |
| Drug Ineffective |
1.3% |
| Ectopic Pregnancy |
1.3% |
| Female Sexual Arousal Disorder |
1.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.6% |
| Drug Use For Unknown Indication |
13.6% |
| Hormone Replacement Therapy |
6.9% |
| Rheumatoid Arthritis |
4.6% |
| Menopause |
4.2% |
| Hypertension |
4.1% |
| Depression |
4.1% |
| In Vitro Fertilisation |
3.9% |
| Hypothyroidism |
3.3% |
| Osteoporosis |
2.9% |
| Crohn's Disease |
2.8% |
| Pain |
2.8% |
| Prophylaxis |
2.6% |
| Anxiety |
2.4% |
| Asthma |
2.0% |
| Migraine |
2.0% |
| Multiple Sclerosis |
2.0% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Osteopenia |
1.8% |
| Insomnia |
1.8% |
|
| Weight Decreased |
10.5% |
| Vomiting |
9.1% |
| Nausea |
8.6% |
| Weight Increased |
8.0% |
| Drug Exposure During Pregnancy |
6.6% |
| Vision Blurred |
6.4% |
| Pain |
4.1% |
| Maternal Exposure During Pregnancy |
3.9% |
| Premature Baby |
3.9% |
| Rash |
3.9% |
| Ventricular Septal Defect |
3.9% |
| Abortion Spontaneous |
3.6% |
| Drug Ineffective |
3.6% |
| Insomnia |
3.6% |
| Ovarian Hyperstimulation Syndrome |
3.6% |
| Vaginal Haemorrhage |
3.6% |
| Pain In Extremity |
3.4% |
| Tremor |
3.4% |
| Fatigue |
3.2% |
| Wrong Technique In Drug Usage Process |
3.2% |
|
| Interacting |
| Hypertension |
31.6% |
| Nephritis |
15.8% |
| Migraine |
10.5% |
| Painful Respiration |
10.5% |
| Respiratory Disorder |
10.5% |
| Smoking Cessation Therapy |
10.5% |
| Contraception |
5.3% |
| Hormone Therapy |
5.3% |
|
| Drug Interaction |
42.9% |
| Rash |
28.6% |
| Glycosylated Haemoglobin Increased |
14.3% |
| Metrorrhagia |
14.3% |
|
